Ichor Medical Systems, Inc.
PrivateLast Round
Debt
Apr 16, 2020
Total Funding Raised
$14.97M
Company Overview
Ichor Medical Systems, Inc. operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Debt round in April 2020.
Ichor Medical Systems, Inc. is a biotechnology company that develops electroporation-based delivery systems for nucleic acid-based drugs and vaccines.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ichor Medical Systems, Inc. Comparables
Compare Ichor Medical Systems, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BEX Co., Ltd. | 77% | |
| Nepa Gene Co., Ltd. | 77% | |
| IGEA S.p.A. | 76% |
For institutional investors. Book with your work email.
Ichor Medical Systems, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Apr 16, 2020 | ||||
| Corporate Funding | Apr 14, 2015 | ||||
| Grant | Nov 18, 2014 | ||||
| Corporate Funding | Feb 5, 2014 | ||||
| Grant | Feb 1, 2011 | ||||
Grant | Sep 5, 2008 |
For institutional investors. Book with your work email.
Ichor Medical Systems, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| National Institute on Aging | Grant |
| U.S. Department of War | Grant |
| Pfizer | Corporate Funding |
| Defense Advanced Research Projects Agency | Grant |
| Defense Threat Reduction Agency | Grant |
| Small Business Administration | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 24, 2025
Monthly visitors increased 145% MoM, reaching 2.7K.
- Nov 12, 2024
Monthly visitors grew 60% MoM, reaching 2.4K.
For institutional investors. Book with your work email.
Ichor Medical Systems, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ichor Medical Systems, Inc.'s valuation, stock price, and market status.
Is Ichor Medical Systems, Inc. a public or private company?
Ichor Medical Systems, Inc. is a private company.
What is the current stock price of Ichor Medical Systems, Inc.?
Ichor Medical Systems, Inc. is a private company, so its shares have no public market price. Caplight tracks Ichor Medical Systems, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ichor Medical Systems, Inc. worth (valuation)?
Valuation information for Ichor Medical Systems, Inc. is not publicly available.
Can I buy Ichor Medical Systems, Inc. stock?
Ichor Medical Systems, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ichor Medical Systems, Inc.'s last funding round?
Ichor Medical Systems, Inc.'s most recent funding round was Debt on April 16, 2020.
Who are the main investors in Ichor Medical Systems, Inc.?
Key investors in Ichor Medical Systems, Inc. include National Institute of Allergy and Infectious Diseases, National Institute on Aging, U.S. Department of War, Pfizer, Defense Advanced Research Projects Agency.
Will Ichor Medical Systems, Inc. IPO soon?
No public IPO plans have been announced for Ichor Medical Systems, Inc..
How can I track Ichor Medical Systems, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Ichor Medical Systems, Inc.'s shares on secondary markets.